FGF2 disruption enhances thermogenesis in brown and beige fat to protect against obesity and hepatic steatosis

Haifang Li^{a,1,*}, Xinzhi Zhang^{a,1}, Cheng Huang^{a,1}, Huan Liu^{a,1}, Shuang Liu^b,
Qiang Zhang^a, Mei Dong^a, Mengjie Hou^a, Yiming Liu^a, Hai Lin^{b,*}

a. State Key Laboratory of Crop Biology, College of Life Sciences, Shandong Agricultural University, Tai'an 271018, China

b. College of Animal Science and Veterinary Medicine, Shandong Agricultural University, Tai'an 271018, China

*Corresponding authors: Haifang Li (haifangli@sda.u.edu.cn),
Hai Lin (hailin@sda.u.edu.cn).

Author contributions: Haifang Li, Xinzhi Zhang, Cheng Huang, and Huan Liu performed *in vitro* and *in vivo* experiments, wrote the manuscript, organized the literature and figures and performed statistical analysis. Haifang Li, and Hai Lin conceived the project, led and supervised the study, and reviewed/edited the manuscript. Shuang Liu, Qiang Zhang, Mei Dong, Mengjie Hou, and Yiming Liu performed experiments and contributed to discussion.

ABSTRACT

Since brown and beige fat expend energy in the form of heat via non-shivering thermogenesis, identifying key regulators of thermogenic functions represents a major goal for development of potential therapeutic avenues for obesity and associated disorders. Here, we identified fibroblast growth factor 2 (FGF2) as a novel thermogenic regulator. FGF2 gene disruption resulted in increased thermogenic capability in both brown and beige fat, which was supported by increased UCP1 expression, enhanced respiratory exchange ratio, and elevated thermogenic potential under cold challenge or β -adrenergic stimulation. Thus, deletion of FGF2 protected mice from high fat-induced obesity and hepatic steatosis. Mechanistically, FGF2 acts in autocrine/paracrine fashions *in vitro*. Exogenous FGF2 supplementation inhibits both PGC-1 α and PPAR γ expression through ERK phosphorylation, thereby limiting PGC-1 α /PPAR γ interactions, and leading to suppression of UCP1 expression and thermogenic activity in brown and beige adipocytes. These findings suggest a viable potential strategy for use of FGF2-selective inhibitors in treatment of combating obesity and related disorders.

Key words: Fibroblast growth factor 2 (FGF2); Thermogenesis; Brown and beige fat; PPAR γ ; PGC-1 α .

1 INTRODUCTION

2 In mammals, there are three types of adipose tissue: white, brown, and beige
3 (*Rosen and Spiegelman, 2014*). While white adipose tissue (WAT) serves as a
4 repository for fatty acids, brown and beige adipocytes burn fatty acids and
5 glucose to generate heat, leading to increased energy expenditure (*Rosen and*
6 *Spiegelman, 2014; Poekes et al., 2015; Wu et al., 2012*). Brown adipocytes
7 derive from a myf5-positive cell lineage, characterized by the presence of
8 small, dense lipid droplets enriched with mitochondria and high expression of
9 uncoupling protein 1 (UCP1), which enables the uncoupling of oxidative
10 phosphorylation from ATP production (*Poekes et al., 2015; Stanford et al.,*
11 *2013*). The expression of UCP1 is driven by peroxisome proliferator-activated
12 receptor gamma (PPAR γ) in cooperation with other transcriptional
13 components, including PPAR γ coactivator-1 α (PGC-1 α) (*Wu et al., 1999;*
14 *Puigserver and Spiegelman, 2003*). In contrast, beige adipocytes emerge from
15 white fat through a process called browning or beiging (*Wu et al., 2012*). The
16 PGC-1 α transcriptional cofactor is also critical important to control
17 white-to-beige fat conversion (*Puigserver and Spiegelman, 2003; Xue et al.,*
18 *2005*). Similar to brown adipocytes, beige adipocytes possess, albeit to a
19 lesser degree, several features indispensable to thermogenesis, such as
20 multilocular lipid droplet morphology, high UCP1 expression, and densely
21 packed mitochondria (*Rosen and Spiegelman, 2014; Wu et al., 2012*).
22 Previous studies have provided evidence that metabolically active brown and
23 beige fat are present in adult humans (*Virtanen et al., 2009; Rogers, 2015*),
24 and their abundance is inversely correlated with fat mass and
25 obesity-associated disorders (*Virtanen et al., 2009; Saito et al., 2009*).

1 Large scale studies have demonstrated the inducibility of both brown and
 2 beige fat (*van Marken Lichtenbelt et al., 2009; Seale et al., 2011; Bachman et*
 3 *al., 2002; Villarroya and Vidal-Puig, 2013*). β -adrenergic signaling induced by
 4 cold exposure and/or β -adrenergic agonists undoubtedly serve as the primary
 5 physiological signal pathway for activation of brown fat thermogenesis and
 6 stimulation of beige adipocyte development (*van Marken Lichtenbelt et al.,*
 7 *2009; Bachman et al., 2002*). In addition, several other secreted factors and
 8 hormones, such as BMP8 (*Whittle et al., 2012*), FGF21 (*Fisher et al., 2012*),
 9 Irisin (*Boström et al., 2012*), and apelin (*Than et al., 2015*), have been shown
 10 to participate in regulating thermogenic activity in brown and/or beige
 11 adipocytes, the activation of which may profoundly decrease fat accumulation
 12 while improving lipid metabolism and glucose homeostasis. Thus, identifying
 13 key regulators of the thermogenic functions of brown and beige adipocytes
 14 represents a major goal for development of potential therapeutic avenues for
 15 obesity and metabolic diseases, such as fatty liver and type II diabetes
 16 (*Villarroya and Vidal-Puig, 2013; Zeve et al., 2009*).

17 Fibroblast growth factor 2 (FGF2), also known as basic FGF (bFGF), is
 18 among the first recognized members of the FGF family (*Powers et al., 2000*).
 19 Through loss-of-function studies, FGF2 has been reported to play essential or
 20 predominant roles in the development of vessels (*Zhou et al., 1998*), nerves
 21 (*Raballo et al., 2000*), and bone (*Hurley et al., 1998; Montero et al., 2000*).
 22 Additionally, the regulation of white adipogenic differentiation by FGF2 has
 23 been rigorously demonstrated (*Kawaguchi et al., 1998; Kakudo et al., 2007;*
 24 *Hao et al., 2016; Xiao et al., 2010*). *Kawaguchi et al.* showed the induction of
 25 *de novo* adipogenesis in reconstituted basement membrane supplemented

1 with FGF2 (*Kawaguchi et al., 1998*). FGF2 significantly enhances the
2 adipogenic differentiation of human adipose-derived stem cells (hASCs) and
3 the expression of PPAR γ (*Kakudo et al., 2007*). Hao *et al.* described a positive
4 correlation between plasma FGF2 levels and fat mass, as well as an increased
5 risk of obesity (*Hao et al., 2016*). However, work by Xiao *et al.* reported that
6 bone marrow stem cells of FGF2-deficient mice showed enhanced lipogenic
7 ability with up-regulation of key adipogenic signaling molecules (*Xiao et al.,*
8 *2010*).

9 Given that FGF2 is correlated with white adipogenesis and fat mass, we
10 hypothesized that it may participate in regulating the thermogenic function of
11 brown and/or beige fat. Here, we unexpectedly discovered that FGF2 gene
12 disruption strongly enhanced the thermogenic action of both brown and beige
13 fat, which led to an increase in energy expenditure and improvement of lipid
14 homeostasis. Consequently, FGF2 gene knockout (KO) alleviated high fat diet
15 (HFD)-induced obesity and hepatic steatosis. Mechanistically, FGF2
16 suppression of PGC-1 α and PPAR γ expression and interaction led to
17 attenuated UCP1 expression and thermogenic activity in brown and beige
18 adipocytes, which was partially mediated by the ERK signaling. These findings
19 established that FGF2 negatively regulates thermogenesis in both brown and
20 beige fat, thus suggesting a strong potential therapeutic approach for the
21 treatment of obesity-associated metabolic disorders via FGF2-specific
22 signaling inhibitors.

23 **RESULTS**

24 **FGF2 gene disruption is associated with enhanced brown fat**
25 **thermogenesis and beiging of white fat.**

1 To evaluate the role of FGF2 in the thermogenic potential of adipose tissues,
2 we generated FGF2-KO mice (genetic background C57BL/6J) (*figure*
3 *supplement 1*). To initially characterize the KO phenotype, we fed 3-week-old
4 male FGF2^{+/+} and FGF2^{-/-} mice with chow diet for 14 weeks and found that
5 although the dynamic changes in body weight and average body weight were
6 indistinguishable between groups at 17 weeks old (*figure supplement 2A,B*),
7 FGF2^{-/-} mice consumed more food than WT littermates during the course of
8 the experiment (*figure supplement 2C*). Correspondingly, FGF2^{-/-} mice had a
9 significantly higher whole feed/gain ratio (*figure supplement 2D*). Notably, the
10 interscapular BAT (iBAT) index of FGF2^{-/-} mice was significantly lower than
11 that of FGF2^{+/+} mice (*Figure 1A,B-figure supplement 2E*). However, in contrast
12 to control, FGF2^{-/-} mice had markedly less subcutaneous fat (*figure*
13 *supplement 2E*). Specifically, the inguinal WAT (iWAT) index was substantially
14 lower ($p=0.057$) in FGF2^{-/-} mice than those in FGF2^{+/+} mice (*Figure 1D*),
15 clearly indicated by the representative graphs of iWAT (*Figure 1C*).
16 Histologically, iBAT in KO was comparable with that in WT tissue (*Figure 1E,F*).
17 However, the UCP1 immuno-reactivity and mtDNA levels in KO iBAT were
18 evidently elevated (*Figure 1G,H*). Interestingly, the transcription levels of
19 thermogenic-associated genes (PPAR γ , PRDM16, PGC-1 α , UCP1, Cidea,
20 C/EBP β , and Dio2) and mitochondrial markers (CytC, and Cox8b) were
21 drastically increased in FGF2^{-/-} iBAT comparing with those in the WT iBAT
22 (*Figure 1J*). Meanwhile, CPT1, a gene associated with fatty acid oxidation, was
23 also transcriptionally activated in iBAT of FGF2^{-/-} mice (*Figure 1J*). In addition,
24 the protein levels of PGC-1 α , UCP1, and PPAR γ were all elevated in iBAT of
25 FGF2^{-/-} mice (*Figure 1K*). Notably, the adipogenic potential of KO iBAT was

1 enhanced, as the mRNA levels of aP2, FAS and LPL, and the protein
 2 expression of aP2 were all highly induced (*figure supplement 3A,C*). These
 3 data indicate that FGF2-KO mice recruit and expend more fat in BAT via
 4 elevated thermogenesis.

5 Moreover, FGF2 disruption led to a marked decrease in lipid droplet size in
 6 iWAT (*Figure 1E,F*), characteristic of reduced triglyceride accumulation or
 7 accelerated triglyceride release. Strikingly, immunofluorescence analysis
 8 revealed greater intensity of UCP1 immuno-reactivity in the iWAT of FGF2-KO
 9 mice (*Figure 1G*). Notably, the mtDNA copy number in KO iWAT was elevated
 10 by ~50% compared with that in the WT tissue ($p < 0.01$) (*Figure 1I*).

11 Furthermore, iWAT from FGF2^{-/-} mice displayed elevated transcription of
 12 thermogenic markers (PPAR γ , PRDM16, PGC-1 α and UCP1), beige
 13 adipocyte-specific genes (TMEM26 and Tbx1), and mitochondrial markers
 14 (CytC, Cox7a, and Cox8b) (*Figure 1L*). Likewise, KO iWAT also showed
 15 increased levels of thermogenic marker proteins, e.g., PPAR γ , PGC-1 α and
 16 UCP1 (*Figure 1M*). Moreover, the transcription of adipogenic-related genes
 17 (C/EBP α , FAS, LPL, and aP2) and the protein expression of aP2 were induced
 18 in KO iWAT (*figure supplement 3B,D*). These results suggest that the
 19 decrease in adipocyte size in FGF2^{-/-} iWAT depends greatly on the degree of
 20 induced beiging and the thermogenic potential rather than on reduced
 21 triglyceride synthesis.

Fig. 1. FGF2 gene disruption leads to enhanced brown fat thermogenesis and beiging of white fat. Tissue samples were collected from 17-week-old FGF2^{+/+} and FGF2^{-/-} mice. (A and B) Representative iBAT images and ratios of iBAT/body weight of FGF2^{+/+} and FGF2^{-/-} mice. (C and D) Representative iWAT images and ratios of iWAT/body weight of FGF2^{+/+} and FGF2^{-/-} mice. Values represent means $\pm$ SEM (n = 7~10). ***p* < 0.01 compared with FGF2^{+/+} mice. (E) Representative scanning electron microscopy images of iBAT (Scale bar = 10 μ m) and iWAT (Scale bar = 100 μ m) sections. (F) Representative images of H&E staining of iBAT and iWAT sections, and the lipid droplet size in iWAT. Scale bar = 50 μ m. (G) Immunofluorescence staining of UCP1 (red) in FGF2^{+/+} and FGF2^{-/-} iBAT and iWAT sections. Scale bar = 100 μ m. (H and I) Quantification of relative mtDNA levels in iBAT (H) and iWAT (I) in FGF2^{+/+} and FGF2^{-/-} mice. (J) The relative mRNA levels of brown adipocyte, lipolysis, and mitochondrial markers in iBAT of FGF2^{+/+} and FGF2^{-/-} mice, determined by qRT-PCR. (K and M) Western blot analysis of PPAR γ , PGC-1 α , and UCP1 protein contents in iBAT (K) and iWAT (M) of FGF2^{+/+} and FGF2^{-/-} mice. Blots were stripped and then probed with β -actin to normalize for variation in loading and transfer of proteins. (L) The relative mRNA levels of beige adipocyte, lipolysis, and mitochondrial markers in iWAT of FGF2^{+/+} and FGF2^{-/-} mice, determined by qRT-PCR. Values represent means $\pm$ SEM (n = 6). **p* < 0.05, ***p* < 0.01 compared with FGF2^{+/+} samples.

1 FGF2-KO mice show increased respiratory exchange ratio (RER) and
2 body temperature, as well as activated responses to cold challenge and
3 β 3-AR stimulation.

4 In view of the role of brown and beige fat in non-shivering thermogenesis, we
 5 compared the respiratory metabolic parameters of the FGF2^{+/+} and FGF2^{-/-}
 6 mice at ambient temperature (25°C). In contrast to WT mice, carbon dioxide
 7 production and RER in FGF2^{-/-} mice both increased substantially in the dark
 8 ($p < 0.05$), and oxygen consumption was also markedly elevated ($p = 0.075$)
 9 (*Figure 2A-C*). In the light, oxygen consumption, carbon dioxide production,
 10 and RER were also higher in KO mice, although not significantly (*Figure*
 11 *2A-C*).

12 Given that increased metabolic rate is often accompanied by higher
 13 thermogenic capacity, we examined the animals' body temperature under cold
 14 challenge conditions. As expected, FGF2^{-/-} mice showed elevated rectal
 15 temperature both prior to and during the 24-hour cold challenge, which was
 16 approximately 1°C higher on average than that of WT littermates at
 17 corresponding time points (*Figure 2D*). By using an infrared camera, we further
 18 found that the surface temperature of KO iBAT was significantly higher than
 19 that of WT, in both untreated and CL316,243 (CL) treatments (*Figure 2I*).

20 In light of our findings of potentiated activation of body temperature in KO
 21 mice under both cold and β 3-AR stimulation conditions, we further examined
 22 the thermogenic markers in treated adipose tissues. In iBAT and iWAT, both
 23 cold challenge and β 3-AR stimulation led to the occurrence of smaller lipid
 24 droplets, and higher expression of thermogenic genes (*Figure 2E-H, J, K,*
 25 *Figure 3*). However, the eWAT adipocytes were unaffected by CL treatment

1 (*figure supplement 4*), consistent with previous research that indicated
 2 brown-like fat cells are seldom observed in epididymal/perigonadal adipose
 3 tissue even under cold challenge or $\beta 3$ -AR stimulation (*Seale et al., 2011*).
 4 Notably, in response to cold challenge, $FGF2^{-/-}$ iBAT exhibited a strongly
 5 potentiated induction of UCP1, and Dio2 mRNA expression, as well as an
 6 elevated UCP1 protein level relative to WT controls (*Figure 2G,H*). However,
 7 following CL injection, the mRNA levels of Cidea, C/EBP β , and HSL were
 8 significantly higher in $FGF2^{-/-}$ iBAT than those in $FGF2^{+/+}$ iBAT (*Figure 2K*).
 9 Moreover, KO iWAT showed a more pronounced increase of PRDM16,
 10 PGC-1 α , UCP1, TMEM26, Tbx1, and CPT1 transcription levels, and a higher
 11 UCP1 protein content upon cold challenge (*Figure 2C,D*), and only an elevated
 12 transcription of Tbx1 following CL treatment (*Figure 2F*) compared with WT
 13 iWAT. These data reflect a highly stronger cold-response and relatively a slight
 14 higher CL-responsiveness by both KO iBAT and iWAT than by WT tissues.

Fig. 2. FGF2-KO mice show increased whole-body energy expenditure and activated thermogenic capability of brown fat. (A and B) O_2 consumption (A) and CO_2 production (B) (expressed as ml/h/kg) measured in 12-week-old FGF2^{+/+} and FGF2^{-/-} mice during a 24-hour period measured using a CLAMS apparatus. (C) RER dynamics calculated by VCO_2/VO_2 . (D) Core body temperature changes in FGF2^{+/+} and FGF2^{-/-} mice following cold challenge, determined by rectal probe every 3 or 6 hours for a 24-h duration. (E and F) Representative images of H&E staining (Scale bar = 50 μm) (E) and immunofluorescence staining of UCP1 (red) (Scale bar = 100 μm) (F) of iBAT sections, under room temperature (RT) or cold challenge for 24 h. (G) qRT-PCR analysis of thermogenic- and lipolysis-related gene expression in FGF2^{+/+} and FGF2^{-/-} iBAT under normal temperature or cold challenge for 24 h. (H) Western blot analysis of UCP1 protein levels in FGF2^{+/+} and FGF2^{-/-} iBAT under RT or cold challenge for 24 h. GAPDH was used as a loading control. (I) Representative thermal images and dorsal interscapular surface temperatures of FGF2^{+/+} and FGF2^{-/-} mice after injection with CL316,243 or PBS control. (J) Representative images of H&E staining of iBAT sections upon PBS or CL316,243 injection. Scale bar = 50 μm . (K) qRT-PCR analysis of thermogenic- and lipolysis-related gene expression in FGF2^{+/+} and FGF2^{-/-} iBAT under PBS or CL316,243 treatments. Data represent means $\pm$ SEM. * $p < 0.05$, ** $p < 0.01$ vs. Vehicle in the same littermates; # $p < 0.05$, ## $p < 0.01$ vs. FGF2^{+/+} mice upon Vehicle treatment; & $p < 0.05$, && $p < 0.01$ vs. FGF2^{+/+} mice upon cold challenge or CL316,243 treatment.

Fig. 3. The thermogenic capability of iWAT exhibits higher potentiation in FGF2-KO mice than in WT, under either cold challenge or β 3-AR stimulation conditions. (A and B) Representative images of H&E staining (Scale bar = 50 μ m) (A) and immunofluorescence staining of UCP1 (red) (Scale bar = 100 μ m) (B) of iWAT sections under RT or cold challenge for 24 h. (C and F) qRT-PCR analysis of thermogenic-, beige adipocyte-, and lipolysis-related gene expression in FGF2^{+/+} and FGF2^{-/-} iWAT under normal temperature or cold challenge for 24 h (C), or following PBS or CL316,243 treatments (F). (D) Western blot analysis of UCP1 protein levels in FGF2^{+/+} and FGF2^{-/-} iWAT under RT or cold challenge for 24 h. GAPDH was used as a loading control. (E) Representative images of H&E staining of iWAT sections following PBS or CL316,243 treatments. Scale bar = 50 μ m. Data represent means $\pm$ SEM. * p <0.05, ** p <0.01 vs. Vehicle in the same littermates; # p <0.05, ## p <0.01 vs. FGF2^{+/+} mice upon Vehicle treatment; & p <0.05, && p <0.01 vs. FGF2^{+/+} mice upon cold challenge or CL316,243 treatment.

FGF2-KO mice show higher stability in lipid homeostasis and amelioration of HFD-induced obesity and hepatic steatosis.

In view of the enhanced function of brown and beige fat resulting from FGF2-KO, its effects on lipid homeostasis were next investigated. Upon chow feeding, significantly reduced plasma TG but not of TCH content was observed in the FGF2-disrupted mice (*figure supplement 5A,B*). The ALT and AST activities were also substantially decreased by FGF2 deficiency ($p=0.089$ for ALT, $p<0.01$ for AST) (*figure supplement 5C,D*). In response to HFD feeding, the plasma TG content was significantly lower in FGF2-KO mice than in WT animals ($p<0.05$), while TCH content, ALT and AST activities were modestly down-regulated ($p>0.05$) (*figure supplement 5A-D*).

1 HFD is prone to induce obesity and ectopic fat deposition in livers.
 2 Therefore, we determined the influence of FGF2 disruption on fat
 3 accumulation and hepatic steatosis following 14 weeks of HFD feeding.
 4 Interestingly, compared with WT, HFD-fed FGF2-KO mice exhibited
 5 significantly lower body weight, with an elevated feed/gain ratio (*figure*
 6 *supplement 6A,B*). Specifically, dual energy X-ray absorptiometry (DXA) and
 7 anatomical imaging revealed vastly lower subcutaneous fat mass in FGF2-KO
 8 mice, compared with that in WT (*Figure 4A-figure supplement 6C*). Moreover,
 9 the iWAT index was greatly down-regulated, while the iBAT index was not
 10 significantly altered in HFD-fed KO mice (*Figure 4B-E*). In addition, the
 11 adipocyte size in iWAT and lipid droplet size in iBAT were generally smaller
 12 among FGF2-KO mice than among WT (*Figure 4F*).

13 Strikingly, the livers of FGF2^{-/-} mice were visibly smaller and the liver
 14 index was slight lower than WT fed with HFD (*Figure 4G,H*), thus indicating
 15 that the HFD-induced fatty liver phenotype may be ameliorated by FGF2
 16 disruption. As expected, H&E and ORO staining of liver sections (*Figure 4I*), as
 17 well as lower hepatic levels of TG and TCH (*Figure 4J,K*), gave further
 18 evidence that FGF2 KO led to alleviation of HFD-induced hepatic steatosis.
 19 Furthermore, liver-specific expression of fat synthesis- or fatty acid
 20 oxidation-associated genes were not significantly different between HFD-fed
 21 KO mice and WT, except for a decrease of ACC (*figure supplement 7*),
 22 suggesting that the amelioration of hepatic fat deposition was not attributable
 23 to the direct alteration of *in situ* fat metabolism.

24 To ascertain whether the amelioration of HFD-induced obesity and
 25 hepatic steatosis mediated by FGF2 deficiency was due to the elevation of

1 thermogenic activity, we compared core body temperature and thermogenic
2 gene expression between HFD-fed WT and KO mice. We found that rectal
3 temperature was significantly higher in HFD-fed KO mice compared to that in
4 WT (*Figure 4L*). Moreover, HFD-fed KO mice displayed substantially greater
5 UCP1 immunostaining in both iBAT and iWAT sections (*Figure 4M*). In addition,
6 the transcriptional levels of PGC-1 α and UCP1 in iBAT, as well as those of
7 PGC-1 α , UCP1, TMEM26, Tbx1, CytC, Cox7a, Cox8b, and Uqcrc2 in iWAT,
8 were all profoundly elevated in HFD-fed KO mice (*Figure 4N,O*). These results
9 suggested that the alleviated HFD-induced obesity and hepatic steatosis
10 phenotype associated with FGF2 deficiency is due in large measure to the
11 enhanced thermogenic ability of brown and beige fats.

Fig. 4. FGF2-KO protects mice against HFD-induced obesity and hepatic steatosis, primarily due to activated thermogenic function in both brown and white fats. (A) Representative DXA images of 14-week-old FGF2^{+/+} and FGF2^{-/-} mice fed with HFD. Red represents areas with more than 50% fat. (B and C) Representative iBAT images and ratios of iBAT/body weight of HFD-fed FGF2^{+/+} and FGF2^{-/-} mice at age of 17 weeks old. (D and E) Representative iWAT images and ratios of iWAT/body weight of HFD-fed FGF2^{+/+} and FGF2^{-/-} mice at age of 17 weeks old. (F) Representative images of H&E staining of iBAT and iWAT sections, and the lipid droplet size in iWAT. Scale bar = 50 μ m. (G and H) Representative liver images (G) and the liver/body weight ratios (H) of FGF2^{+/+} and FGF2^{-/-} HFD-fed mice. (I) Representative images of H&E and ORO staining of liver sections. Scale bar = 50 μ m. (J and K) TG (J) and TCH (K) contents in the livers of HFD-fed FGF2^{+/+} and FGF2^{-/-} mice. (L) The core body temperature of HFD-fed FGF2^{+/+} and FGF2^{-/-} mice. (M) Immunohistochemistry staining of UCP1 (brown) in HFD-fed FGF2^{+/+} and FGF2^{-/-} iBAT and iWAT sections. Scale bar = 50 μ m. (N and O) The relative mRNA levels of brown/beige adipocyte-, lipolysis-, and mitochondrial-related markers in iBAT (N) and iWAT (O) of HFD-fed FGF2^{+/+} and FGF2^{-/-} mice, determined by qRT-PCR. Data represent means $\pm$ SEM (n = 8). * p <0.05, ** p <0.01 vs. HFD-fed FGF2^{+/+} mice.

FGF2-KO-derived brown and beige adipocytes exhibit higher thermogenic gene expression *in vitro*

Given the enhancement of *in vivo* thermogenesis resulting from FGF2 disruption, *in vitro* experiments were conducted to compare the thermogenic gene expression levels between WT- and KO-derived adipocytes. We found that the differentiated FGF2^{-/-} brown adipocytes exhibited higher thermogenic gene transcription, including PPAR γ , PGC-1 α , UCP1, and C/EBP β , as well as lipolysis markers (HSL and CPT1) and the mitochondrion marker mtTF than did controls (*Figure 5A*). Similarly, the protein expression of PPAR γ , PGC-1 α , and UCP1 was enhanced in FGF2^{-/-} brown adipocytes, compared to that in WT cells (*Figure 5B*). In addition, the mitochondria density and the UCP1 immuno-reactivity were also elevated in KO brown adipocytes (*Figure 5C,D*). We used isoproterenol (ISO) to induce the beiging of *in vitro* cultured WT- and KO-derived white adipocytes, and identified that the beiging-associated genes, including PPAR γ , PGC-1 α , UCP-1, and TMEM26 were all activated in KO cells (*Figure 5E*). Moreover, in contrast to WT, the KO beighed white adipocytes displayed enhanced PGC-1 α and UCP1 protein levels, mitochondria density, and UCP1 immuno-reactivity (*Figure 5F-H*). These results indicated that FGF2-KO brown and beige adipocytes also show higher thermogenic gene expression *in vitro*, hinting the antocrine regulation of FGF2 on thermogenesis.

Fig. 5. FGF2^{-/-}-derived brown and beige adipocytes exhibit higher thermogenic gene expression *in vitro*. (A) Relative mRNA levels of brown adipocyte, lipolysis, and mitochondrial genes in differentiated FGF2^{+/+} and FGF2^{-/-} brown adipocytes. (B) Western blot analysis of PPARγ, PGC-1α, UCP1, p-ERK, and ERK protein contents in brown adipocytes derived from FGF2^{+/+} and FGF2^{-/-} mice. GAPDH was used as a loading control. (C and D) MitoTracker staining (red) (C) and immunofluorescence staining of UCP1 (red) (D) in brown adipocytes derived from WT and KO mice. The nuclei (blue) were stained with DAPI. Scale bar = 100 μm. (E) Relative mRNA expression beige adipocyte, lipolysis, and mitochondrial genes in differentiated FGF2^{+/+} and FGF2^{-/-} white adipocytes. (F) Western blot analysis of PPARγ, PGC-1α, UCP-1, p-ERK, and ERK protein contents in beiging white adipocytes derived from FGF2^{+/+} and FGF2^{-/-} mice. GAPDH was used as a loading control. (G and H) MitoTracker staining (red) (G) and immunofluorescence staining of UCP1 (red) (H) of beiging white adipocytes derived from WT and KO mice. The nuclei (blue) were stained with DAPI. Scale bar = 100 μm. Data represent means ± SEM (n = 6). *p < 0.05, **p < 0.01 compared with that from FGF2^{+/+} mice.

Exogenous FGF2 application inhibits expression of thermogenic genes in cultured brown and white adipocytes, partially through activating ERK phosphorylation.

Previous reports have established that FGF2 acts in either an autocrine or a paracrine fashion via FGFR1 binding that requires concurrent interaction with heparin (HP) (Zhou *et al.*, 1998). Thus, we supplemented exogenous FGF2 together with HP to the cell culture medium to test the alteration of thermogenic genes. In the induced brown adipocytes, FGF2 plus HP supplementation (10 ng/mL each) strongly suppressed the mRNA levels of PGC-1 α , UCP1, and CytC, as well as the protein expression of PGC-1 α (*figure supplement 8*). Thus, we used FGF2 in conjunction with HP in all the following experiments. Notably, the FGFR1 inhibitor SSR128129E (SSR) was able to antagonize the inhibition by FGF2 on thermogenic gene expression (*figure supplement 9*). This supported the paracrine regulation of FGF2 on thermogenesis of brown adipocytes.

As a growth factor, FGF2 participates in activation of some growth-related signals, such as the ERK signaling pathway (Kim *et al.*, 2015). We observed a decrease of p-ERK/ERK ratio in both cultured FGF2^{-/-} brown and beige adipocytes (*Figure 5B,F*). Herein, two-day-induced WT brown adipocytes were treated with exogenous FGF2 over a one-hour time course to further test the involvement of ERK signaling. We can see that exogenous FGF2 application led to a rapid induction of ERK1/2 phosphorylation (*Figure 6A*). Furthermore, an ERK-specific inhibitor PD0325901 (PD) was included in the differentiation medium for WT brown adipocytes in the absence or presence of FGF2. Interestingly, FGF2 transcriptional suppression of thermogenic markers was

1 substantially decreased by PD application (*Figure 6B*). Moreover, PD also
 2 negated the FGF2-mediated blockade of PGC-1 α , UCP1, and PPAR γ protein
 3 expression (*Figure 6C*). These data clarify the involvement of ERK signaling in
 4 the FGF2-mediated transcriptional and translational blockade of thermogenic
 5 genes.

6 Strikingly, FGF2 also robustly inhibited the expression of beiging-related
 7 genes in ISO-induced beiging white adipocytes, but were transcriptionally
 8 restored by application of the FGFR1 inhibitor SSR (*figure supplement 10*).
 9 These results demonstrate that FGF2 also plays a negative regulatory role in
 10 the beiging of white adipocytes through a paracrine-dependent manner.
 11 Besides, the activated ERK signaling contributed to negative regulation of
 12 beiging of white adipocytes by FGF2 (*figure supplement 11A-C*).

13 Together, these data illustrate that exogenous FGF2 application is able to
 14 inhibit thermogenic gene expression in both brown and beige adipocytes in
 15 paracrine fashions, which at least partially via activation of ERK1/2
 16 phosphorylation.

Fig. 6. FGF2 inhibits thermogenic gene expression in brown adipocytes *in vitro*, via ERK signaling-induced PPAR γ and PGC-1 α suppression. (A) Expression of ERK1/2 and p-ERK1/2 proteins in differentiated brown SVFs after supplementation with FGF2 or Vehicle for 5, 15, 30, and 60 min, determined by western blotting. Blots were stripped and probed again with GAPDH to normalize for variation in loading and transfer of proteins. (B) Relative mRNA levels of brown adipocyte-, lipolysis-, and mitochondrial-associated genes in Vehicle, FGF2, PD, or PD+FGF2 -treated brown adipocytes, determined by qRT-PCR. GAPDH serves as a loading control. (C) Protein expression of PPAR γ , PGC-1 α , and UCP1 in cells treated as in (B), determined by western blotting. β -actin serves as a loading control. (D) Relative mRNA levels of brown adipocyte-, lipolysis-, and mitochondrial-associated genes in Vehicle, FGF2, Rosi, Rosi+FGF2, Lenti-control, Lenti-control+FGF2, Lenti-PGC-1 α , Lenti-PGC-1 α +FGF2, or Rosi+Lenti-PGC-1 α +FGF2 -treated brown adipocytes, determined by qRT-PCR. (E) Protein expression of PPAR γ , PGC-1 α , and UCP1 in brown adipocytes treated with Vehicle, FGF2, Rosi, Rosi+FGF2, Lenti-PGC-1 α +FGF2, or Rosi+Lenti-PGC-1 α +FGF2, determined by western blotting. (F and G) MitoTracker staining (red) (F) and immunofluorescence staining of UCP1 (red) (G) of treated brown adipocytes. The nuclei (blue) were stained with DAPI. Scale bar = 100 μ m. Data represent means $\pm$ SEM. * p <0.05, ** p <0.01 vs. Vehicle; # p <0.05, ## p <0.01 vs. FGF2 treatment.

PPAR γ and PGC-1 α cooperatively participate in FGF2 suppression of thermogenic gene expression in brown and white adipocytes.

The PPAR γ transcription factor controls thermogenic gene expression in conjunction with other regulatory co-factors, such as PGC-1 α (Puigserver and Spiegelman, 2003; Ahmadian et al., 2013). Notably, accompanied by induction of UCP1 expression, PPAR γ and PGC-1 α mRNA and protein levels were also elevated by FGF2 deficiency in both iBAT and iWAT (Figure 1J-M). Similarly, in *in vitro* cultures of brown and beige white adipocytes, FGF2 substantially suppressed PPAR γ and PGC-1 α accumulation (Figure 6B,C-figure supplement 11B,C). We therefore employed rosiglitazone (Rosi), a PPAR γ -specific agonist, and a recombinant PGC-1 α expression lentivirus construct (Lenti-PGC-1 α) to test whether PPAR γ and PGC-1 α performed essential functions in the FGF2-mediated pathway for suppression of thermogenic gene expression.

1 In differentiated brown adipocytes, we found that Rosi counteracted FGF2
2 inhibition of UCP1 and Cidea transcription, and Lenti-PGC-1 α also restored
3 UCP1, Cidea, and Dio2 expression (*Figure 6D*). Although exogenous FGF2
4 supplementation led to only negligible repression of mitochondrial genes, both
5 Rosi and Lenti-PGC-1 α treatment significantly enhanced the mRNA levels of
6 these markers (*Figure 6D*). Furthermore, we observed that Rosi and
7 Lenti-PGC-1 α generally acted synergistically (*Figure 6D,E*). It is likely that the
8 FGF2-mediated reduction in UCP1 protein content was counteracted primarily
9 through Rosi activity, while Lenti-PGC-1 α played a cooperative role (*Figure*
10 *6D,E*). MitoTracker and immunostaining also showed increased accumulation
11 of mitochondria and UCP1 due to Rosi and Lenti-PGC-1 α abolition of
12 FGF2-mediated suppression of thermogenic gene expression in brown
13 adipocytes ((*Figure 6F,G*).

14 In ISO-induced beige white adipocytes, Rosi largely negated the FGF2
15 blockade of beige-related markers, including UCP1, TMEM26, and Tbx1,
16 while Lenti-PGC-1 α alone did not significantly restore expression of these
17 markers (*figure supplement 11D*). However, Lenti-PGC-1 α substantially
18 antagonized the FGF2 inhibition of mitochondrial marker (CytC, Cox7a, Cox8b,
19 and Aco2) transcription, while Rosi treatment led to only a moderate increase
20 in expression of these markers (*figure supplement 11D*). In addition, the
21 FGF2-reduced UCP1 protein expression was only markedly recovered in
22 treatment of Rosi together with Lenti-PGC-1 α (*figure supplement 11E*). In
23 beige white adipocytes, further evidences for PPAR γ and PGC-1 α function in
24 the FGF2 pathway for thermogenic gene suppression were observed by Rosi-

1 and Lenti-PGC-1 α -restored accumulation of MitoTracker and immunostained
2 UCP1 (*figure supplement 11F,G*).

3 The expression levels of UCP1 determine thermogenic capability for both
4 brown and beige adipocytes (*Poekes et al., 2015; Wu et al., 2012*). Because
5 both PPAR γ and PGC-1 α function downstream of FGF2 transcriptional
6 suppression of thermogenic genes, we further examined whether FGF2
7 interfered with interactions between PPAR γ /PGC-1 α and the UCP1 promoter
8 region. The interaction of PPAR γ with PGC-1 α was detectable in both brown
9 and beige adipocytes (*Figure 7A,B*). While exogenous FGF2 protein
10 application to cultures of both adipocyte types led to decreased interactions
11 between PGC-1 α with PPAR γ , the addition of the FGFR1 inhibitor (SSR)
12 alleviated the inhibitory impact of FGF2 (*Figure 7A,B*). Results of chromatin
13 immunoprecipitation (ChIP) assay indicated that PPAR γ interaction with the
14 UCP1 promoter was significantly decreased in the presence of FGF2, but
15 largely rescued by Rosi treatment and Lenti-PGC-1 α infection. Moreover, Rosi
16 and Lenti-PGC-1 α functioned synergistically to recover the FGF2-suppressed
17 UCP1 promoter binding with PPAR γ (*Figure 7C,D*). Luciferase reporter activity
18 driven by the UCP1 promoter showed that Rosi and Lenti-PGC-1 α both and
19 synergistically restored UCP1 expression that was decreased by FGF2 (*Figure*
20 *7E*).

21 Taken together, these results indicate that although PPAR γ and PGC-1 α
22 individually provide different contributions in brown and beiging white
23 adipocytes, the two factors work together in the negative regulation of FGF2
24 on thermogenic gene expression.

Fig. 7. PGC-1α and PPARγ cooperatively participate in FGF2 inhibition of UCP1 expression in both brown and white adipocytes. (A) Co-IP analysis of association between PGC-1α and PPARγ in differentiating brown adipocytes treated with Vehicle, FGF2, SSR, or SSR+FGF2. (B) Co-IP analysis of association between PGC-1α and PPARγ in differentiating white adipocytes treated with Vehicle, FGF2, SSR, or SSR+FGF2. (C) ChIP assay of the association between PPARγ and the UCP1 promoter in brown adipocytes treated with Vehicle, FGF2, Rosi+FGF2, Lenti-control+FGF2, Lenti-PGC-1α+FGF2, or Rosi+Lenti-PGC-1α+FGF2. (D) ChIP assay of the interaction between PPARγ and the UCP1 promoter in white adipocytes, in the presence of ISO. (E) Dual luciferase activity driven by UCP1 transcription in HEK293 cells treated with Vehicle, FGF2, Rosi+FGF2, Lenti-control+FGF2, Lenti-PGC-1α+FGF2, or Rosi+Lenti-PGC-1α+FGF2. * $p<0.05$, ** $p<0.01$ vs. Vehicle; # $p<0.05$, ## $p<0.01$ vs. FGF2 treatment.

DISCUSSION

Here, we showed that FGF2 disruption stimulated the thermogenic potential of both brown and beige fat, uncovering a previously unrecognized role of FGF2 in adipocyte function. The major findings of this study, as illustrated in *Figure 8*,

are as follows: a) FGF2-KO mice exhibit an elevated capacity for thermogenesis in both brown and beige fats, thus showing higher energy expenditure under both basal and β 3-AR stimulation; b) FGF2 gene deletion protects against HFD-induced obesity and hepatic steatosis in mice; c) FGF2 leads to ERK phosphorylation, which inhibits the expression of and interactions between PPAR γ and PGC-1 α , thereby suppressing thermogenic gene expression.

Fig. 8. Proposed model of FGF2 regulation the thermogenic potential of brown and beige fat. (A) FGF2 deficiency increases brown fat function, and the degree of beige in white fat, thereby activating thermogenesis under both basal and cold challenge conditions. Consequently, FGF2-KO mice show alleviation of high fat-induced obesity and hepatic steatosis. (B) FGF2 stimulates phosphorylation of ERK1/2 in brown and beige adipocytes and thereafter inhibits the expression of both PPAR γ and PGC-1 α . The suppression of protein interactions between PPAR γ and PGC-1 α decreases thermogenic gene expression and the thermogenic potential of brown and beige adipocytes.

Although several FGF family members, including FGF2, have been established to play unique roles in fat metabolism and/or function, white fat has received considerably more attention (Jonker *et al.*, 2012; Badman *et al.*, 2007; Dutchak *et al.*, 2012; Sakaue *et al.*, 2002). For example, Jonker *et al.* reported on the role of the PPAR γ -FGF1 signaling axis in adaptive adipose remodeling, in which FGF1-KO mice show impaired adipose expansion under high fat

1 conditions (*Jonker et al., 2012*). FGF21 functions in a feed-forward loop to
 2 regulate PPAR γ activity via prevention of sumoylation, and FGF21-KO mice
 3 show attenuated expression of PPAR γ -dependent genes and decreased body
 4 fat (*Dutchak et al., 2012*). Furthermore, Fisher *et al.* showed that FGF21 can
 5 enhance PGC-1 α protein expression as well as the browning of WAT in
 6 adaptive thermogenesis in an autocrine/paracrine manner (*Fisher et al., 2012*).
 7 Contrary to the role of FGF21, we found that FGF2 negatively affects PGC-1 α
 8 mRNA and protein abundance, subsequently blocking the white-to-brown fat
 9 switch, which was supported by the accumulation of more beige adipocytes in
 10 FGF2-KO mice. In addition, we observed an increase in mtDNA copy number
 11 and thermogenic gene expression in FGF2-KO BAT. To our knowledge, these
 12 findings provide the first description of FGF2 function in thermogenic
 13 regulation in both brown and beige fat cells.

14 As expected, oxygen consumption, RER, and body temperature were all
 15 increased due to FGF2 disruption, which was consistent with the increase in
 16 whole-body metabolic rate associated with activated brown and/or beige fat
 17 function (*Bagchi et al., 2018; Yao et al., 2017*). Accordingly, FGF2 disruption
 18 amplified the enhancement of cold-induced thermogenic activity for both brown
 19 and white fat cells. Thermogenic activity of activated brown and/or beige fat is
 20 often accompanied by improved metabolic homeostasis (*Poekes et al., 2015;*
 21 *Saito et al., 2009*). Surprisingly, even FGF2^{-/-} mice fed on a chow diet
 22 displayed evident improvements in lipid homeostasis. However, adipogenic
 23 gene expression increased rather than decreased in KO iWAT and iBAT. This
 24 finding supported the potential contribution to improved lipid homeostasis
 25 made by increasing thermogenic capability of fat tissues.

1 In addition, high fat-feeding experiments indicated that FGF2^{-/-} mice were
2 resistant to diet-induced obesity and hepatic steatosis. These results were
3 similar to findings from other studies in which the abundance and/or the
4 thermogenic ability of brown or beige cells were increased in KO strains (such
5 as retinoblastoma protein, tumor necrosis factor- α receptor 1, liver X receptor,
6 and histone deacetylase 11) that also exhibited improved lipid homeostasis
7 and resistance to HFD-induced obesity and/or fatty liver (*Bagchi et al., 2018*;
8 *Hansen et al., 2004*; *Romanatto et al., 2016*; *Wang et al., 2008*). Neither fat
9 synthesis nor fat oxidation was attributable to the triglyceride reduction in the
10 livers of HFD-fed FGF2 KO mice, which further confirmed the contribution of
11 fat thermogenesis on the amelioration of obesity-associated hepatic steatosis
12 phenotypes. These findings suggest a fascinating possibility that priming
13 brown and beige fat function may combat obesity and related metabolic
14 disorders via inhibition of FGF2 signaling.

15 Given the positive effects of FGF2 disruption on brown fat function and the
16 degree of beiging in white fat cells *in vivo*, we further showed brown and white
17 adipocytes from FGF2-KO mice had higher expression of thermogenic
18 markers *in vitro*, indicating FGF2 took action in an autocrine fashion.
19 Additionally, exogenous FGF2 supplementation suppressed thermogenic gene
20 expression, which demonstrated that FGF2 also acted via paracrine pathways.
21 The cell-autonomous regulation of FGF2 on thermogenesis is similar with that
22 of FGF21, although in contrast, FGF21 enhances the browning of white fat
23 (*Fisher et al., 2012*). Furthermore, we found FGF2 application stimulated
24 ERK1/2 phosphorylation during induced brown adipogenesis and white
25 adipocyte beiging, while blocking ERK signaling counteracted FGF2

1 suppression of thermogenic genes. These results suggested the involvement
2 of ERK signaling in FGF2-mediated negative regulation of thermogenesis,
3 which is supported by previous reports showing that FGF2 stimulates ERK
4 phosphorylation to inhibit hASC adipogenesis (*Kim et al., 2015*).

5 We ultimately examined the pathway by which FGF2-induced ERK
6 activation inhibits thermogenic gene expression and discovered that
7 suppression of ERK signaling enhanced both PPAR γ and PGC-1 α expression,
8 subsequently increasing the abundance of UCP1. PPAR γ is a key transcription
9 factor that controls both adipogenic and thermogenic gene expression
10 (*Ahmadian et al., 2013*). However, PPAR γ functions coordinately with other
11 components, *e.g.*, PGC-1 α , to activate thermogenesis (*Wu et al., 1999; Xue et*
12 *al., 2005*). Notably, we found that PPAR γ and PGC-1 α abundance were
13 positively correlated with UCP1 expression *in vivo*. Supplementation with
14 PPAR γ -specific agonist and lentiviral expression of PGC-1 α *in vitro* blocked
15 FGF2 regulatory function, and synergistically enhanced UCP1 expression,
16 thereby demonstrating the essential regulatory contributions of PPAR γ and
17 PGC-1 α in modulating FGF2 activity, in agreement with previous studies which
18 showed PGC-1 α is a critical transcription co-factors for UCP1 expression (*Wu*
19 *et al., 1999; Xue et al., 2005*). Concurrent with UCP1 activation, PGC-1 α
20 expression significantly increased in both FGF2-KO iWAT and iBAT, as well as
21 during cold challenge. Interestingly, Lenti-PGC-1 α only moderately increased
22 UCP1 expression, but in the presence of Rosi profoundly elevated UCP1,
23 consistent with previous reports showing that PGC-1 α interacts with PPAR γ to
24 co-activate genes associated with thermogenesis (*Wu et al., 1999*). In sum,
25 these results indicate that FGF2 application leads to ERK phosphorylation,

thereby inhibiting PPAR γ and PGC-1 α expression and interactions in order to suppress thermogenic gene expression in both brown and beige adipocytes.

In conclusion, we describe an unreported role for FGF2 in the negative regulation of thermogenesis of brown and beige fat in a cell-autonomous manner. FGF2-KO mice show elevated thermogenic ability of brown and beige fat, with higher energy expenditure and improved lipid homeostasis, as well as protection against HFD-induced obesity and hepatic steatosis. Inhibition of PPAR γ and PGC-1 α expression and interactions via ERK phosphorylation at least partially contributes to the negative regulation of thermogenic gene expression by FGF2. Future studies will further elucidate the contribution of autocrine FGF2 to the inhibition of brown fat function and white-to-beige fat conversion by using mice with adipocyte-specific conditional deletion of FGF2. In addition, further investigation is needed to determine the role of FGF2-specific signaling inhibitors in the thermogenic activities of adipose tissues *in vivo* in order to develop better potential clinical strategies to combat obesity and related disorders.

Methods

Reagents. Recombinant FGF2 was from PeproTech (Rocky Hill, USA). PD and Rosi were purchased from Selleck (USA). CL was from Cayman Chemical (USA). PGC-1 α expression lentivirus (Lenti-PGC-1 α) and control lentivirus (Lenti-control) were from Genechem (Shanghai, China). The following primary antibodies were used: GAPDH (AB0038, Abways, China), β -actin (P60709, Abways, China), FGF2 (sc-74412, Santa Cruz), PPAR γ (sc-7273, Santa Cruz),

PGC-1 α (sc-13067, Santa Cruz), UCP1 (ab15517, Abcam), aP2 (sc-271529, Santa Cruz), ERK (#4695, CST), and p-ERK (#9101, CST).

Animals. All experiments were conducted in FGF2-KO (FGF2^{-/-}) mice and WT (FGF2^{+/+}) littermates with the same genetic background (C57BL/6J). KO was conducted using clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR-associated 9 methods. Two single-guide RNAs (sgRNA1: GGAGACAGAGGCCTGCAATG and sgRNA2: TCTCGCGGACGCCATCCAC G) were designed to target promoter and exon 1. Successful deletion was confirmed by PCR genotyping using tail genomic DNA with primers 5'-TCTAACAACCTGAGGCAGGGCAA-3' and 5'-GAAGTGGCAACTCAC CGTG TG-3'. FGF2 heterozygous (+/-) mice were bred to obtain FGF2-KO mice and their WT littermates.

Mice were housed in a temperature- and humidity-controlled, pathogen free facility with 12 h dark-light cycles. For HFD studies, animals were fed a diet that 45% kcal from fat (Ref. D12451, Research Diets Inc., USA). The body weight, food and water intake of mice were recorded weekly. The body composition of mice was determined by dual energy X-ray absorptiometry (DXA) (MEDIKORS, Korea). At the end of the experiment, animals were kept fasting for 12 h and sacrificed by isoflurane inhalation followed by cervical dislocation. iBAT, iWAT, eWAT and liver tissues were harvested and weighed. All animal experiments were performed in accordance with the guidelines for the Care and Use of Laboratory Animals, and animal maintenance and

1 experimental procedures were approved by the Animal Care and Use
2 Committee of Shandong Agricultural University, China.

3 **Histology, H&E staining, ORO staining, and immunohistochemistry/**
4 **immunofluorescence analysis.** iBAT, iWAT, eWAT and liver tissues were
5 fixed in 4% paraformaldehyde for more than 24 h, and embedded in paraffin.
6 Paraffin samples were sectioned (5 μ m) and stained with hematoxylin and
7 eosin for histochemical examination. Area of adipocytes in adipose tissues
8 were measured by using an image software (Nikon, Japan). For ORO staining,
9 liver samples were frozen in liquid nitrogen and sectioned at 8 μ m in thickness
10 using a cryostat. The sections were stained with ORO solution for 10 min. After
11 washing with water, sections were stained for 1 min in hematoxylin. For
12 immunohistochemistry/immunofluorescence, de-paraffinized iBAT and iWAT
13 sections were blocked with FBS, incubated with specific UCP1 primary and
14 HRP-/Alexa Fluor 555- conjugated secondary antibodies, and detected
15 accordingly.

16 **Scanning electron microscopy (SEM).** iBAT and iWAT samples were fixed
17 with 2% glutaraldehyde, and post-fixed in 1% osmium tetroxide for 1 h,
18 dehydrated in graded concentrations of ethanol and 100% acetone. The
19 specimens were dried at the critical point. Subsequently, the specimens were
20 stuck on a colloidal silver, and sputtered with gold by a MED 010 coater
21 (Balzers) and analyzed with a scanning electron microscope (JEOL, Japan).

1 **Quantification of mtDNA copy number.** Equal amounts of WT and KO iBAT
2 and iWAT were used to extract total DNA after digestion with proteinase K,
3 respectively. The isolated DNA was used to amplify mtDNA using primers for
4 the mitochondrial cytochrome c oxidase subunit 2 (COX2) gene, with the
5 Rsp18 nuclear gene as an internal control of genomic DNA, as described
6 previously (Yao *et al.*, 2017).

7 **Determination of plasma parameters.** Whole blood was collected from
8 eyeball into heparinized containers and plasma was obtained after
9 centrifugation. Fasting triglyceride (TG) and total cholesterol (TCH) levels were
10 determined by commercial kits (Nijc Bio Institute, China). Plasma alanine
11 aminotransferase (ALT) and aspartate aminotransferase (AST) activities were
12 measured on Cobas Integra 400 Clinical Analyzer (Roche Diagnostics).

13 **Hepatic TG and TCH content determination.** Liver tissue (500 mg) was
14 homogenized in 300 μ L RIPA lysis buffer in a Polytron disrupter. The
15 homogenate was centrifuged at 12,000g for 5 min, and the supernatant was
16 collected. TG and TCH content in the tissue was quantified with commercial
17 assay kits (Dongou, China), which was normalized to total protein and
18 expressed as mmol/g total protein.

19 **Metabolic studies.** Mice were housed in individual metabolic cage system
20 (TSE LabMaster, TSE system, Germany) with free access to water and food,
21 and allowed to acclimate for a 24 h period, then data was collected every 9 min
22 for another 24 h. O₂ consumption (VO₂) and CO₂ production (VCO₂) were

1 measured by the TSE system, and RER were calculated using the
2 manufacturer's system software.

3 **Infrared thermography.** The temperature of WT and KO mice was recorded
4 with an infrared camera (FOTRIC 225) and analyzed with a specific software
5 (FOTRIC Tools Software). At least five pictures of each mouse were taken and
6 analyzed.

7 **Cold challenge and β 3-AR agonist treatment.** For cold exposure experiment,
8 WT and FGF2^{-/-} mice were kept at a 5 °C room for 24 hours. Core body
9 temperature was monitored using a rectal probe every 3 or 6 hours for the 24
10 h-duration of the study. Twenty four hours' later, mice at RT and cold room
11 were sacrificed to collect iBAT and iWAT for further thermogenic-capability
12 determinations. For β 3-AR agonist treatment, CL was intraperitoneally injected
13 into mice at 0.5 mg kg⁻¹ body weight/day. Three days later, iBAT and iWAT
14 were collected to determine the mRNA expression of thermogenic genes and
15 make paraffin slices.

16 **Isolation of brown and white SVFs, in *vitro* differentiation and treatments.**

17 Brown and white SVFs were obtained and induced to differentiate into mature
18 adipocytes, respectively, as previously described with minor modification
19 (Seale *et al.*, 2011; Bagchi *et al.*, 2018). During the induced adipogenic
20 process, 1 μ M PD, 1 μ M Rosi or 0.5 μ M SSR were added to some cell culture
21 dishes, in the presence or absence of 10 ng/mL FGF2 and 10 ng/mL HP.

1 **Quantitative real-time PCR (qRT-PCR).** Total RNA was extracted from
2 tissues or cells using RNAiso Plus Reagent, and converted to cDNA using the
3 HiScript II Q RT SuperMix for qPCR Kit (Vazyme, China). qRT-PCR was
4 performed with SYBR green fluorescent dye (Takara, Japan) using a
5 Real-Time PCR System (Applied Biosystems). Transcript levels were
6 quantified using the $2^{-\Delta\Delta C_t}$ method values to that of GAPDH. Primers used were
7 shown in *table supplement 1*.

8 **Western blotting.** Protein lysates were obtained from tissues or cells using
9 RIPA lysis buffer containing protease and phosphatase inhibitor cocktails
10 (Roche, USA). Western blotting was conducted as described previously (Yao
11 *et al.*, 2017).

12 **Lentivirus infection.** For experiments with lentivirus, different recombinant
13 lentiviruses were individually supplemented into 50% confluency SVFs at 5
14 MOI with 6 µg/mL polybrene, and the medium was refreshed 24 hours after
15 infection. After recovering for another 72 hours, the infected cells were induced
16 for differentiation together with other treatments.

17 **MitoTracker staining.** Different-treated brown and beige adipocytes were
18 stained with MitoTracker Red CMXRos (20 nM) (CST, #9082) in DMEM
19 containing 15% FBS at 37 °C for 30 min. Following washing twice with DMEM
20 containing 15% FBS, the cells were incubated with DAPI (1 µg/mL) for 5 min at
21 RT. The intracellular MitoTracker-stained mitochondria were detected using a

1 confocal laser scanning microscopy (CLSM) (Zeiss, Germany). Images were
2 acquired and processed with the same setting for different treatments.

3 **Immunofluorescence staining of UCP1.** For immunofluorescence staining,
4 formalin-fixed and Triton X 100- permeabilized brown and beige adipocytes
5 were pre-incubated with a blocking buffer (PBS containing 5% FBS) for 60 min,
6 and incubated with UCP1 antibody (1:100 dilution) in blocking buffer at 4 °C
7 overnight. Subsequently, the slides were washed, and incubated with Alexa
8 Flour 555-conjugated secondary antibody (1:500 dilution). After staining with
9 DAPI (1 µg/mL) for 5 min, images were acquired by using a CLSM (Zeiss,
10 Germany) and processed with the same setting for different treatments.

11 **Co-IP.** To determine the influence of FGF2 and/or FGFR1 inhibitor SSR on
12 interaction of PPAR γ with PGC-1 α in differentiating brown and beige
13 adipocytes, co-IP was performed as previously described (*Bagchi et al., 2018*),
14 with some minor modifications.

15 **ChIP assay.** To determine the interaction of PPAR γ with the promoter of
16 UCP1, CHIP assay was performed using a CHIP Assay Kit, as described
17 previously (*Yao et al., 2017*). The primers for UCP1-promoter were listed in
18 *table supplement 1*.

19 **Dual luciferase reporter assay.** HEK293 cells cultured in 96-well plates were
20 cotransfected with 1000 ng/mL of pGL3-basic, pGL3-UCP1p, or pGL3-control
21 along with 50 ng/mL of pRL-TK, respectively. Six hours later, the cells were
22 infected with Lenti-control or Lenti-PGC-1 α recombinant viruses in some

1 treatments. After infection with 24 hours, the cells were treated with Vehicle,
2 FGF2, Rosi+FGF2, Lenti-control+FGF2, Lenti-PGC-1 α +FGF2, or
3 Rosi+Lenti-PGC-1 α +FGF2 for 2 days. Subsequently, the treated cells were
4 washed and lysed in 20 μ L of lysis buffer (Dual reporter assay system,
5 Promega). The firefly luciferase activity was examined according to the
6 protocols, and efficiency was normalized to renilla luciferase activity directed
7 by a cotransfected control plasmid pRL-TK.

8 **Statistical analysis.** Statistical analysis was performed on data from at least 3
9 repeated experiments. All data were presented as means $\pm$ SEM. Significant
10 difference between treatments was tested by one-way ANOVA or two-sample
11 student t-test. $p < 0.05$ was regarded as significant.

12 **Acknowledgments**

13 The authors would like to thank Zizhang Zhou (Shandong Agricultural
14 University), Xuguo Zhou (University of Kentucky), and Yingli Shang (Shandong
15 Agricultural University) for their assistance in preparation of this manuscript.

16 Thanks will be given to Yanqin Wang (Hebei Normal University) for assistance
17 with lentivirus production. This work was supported by the Taishan Scholars
18 Program [No. 201511023], the National Key Research and Development
19 Program of China (2017YFE0129800), Funds of Shandong “Double Tops”
20 Program, and Natural Science Foundation of Shandong Province, China [No.
21 ZR2019MC016].

22 **References**

- 1 Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, Evans RM. 2013. PPAR γ
2 signaling and metabolism: the good, the bad and the future. *Nature Medicine*
3 **19**:557-566. doi: 10.1038/nm.3159. Epub 2013 May 7
- 4 Bachman ES, Dhillon H, Zhang CY, Cinti S, Bianco AC, Kobilka BK, Lowell BB. 2002.
5 betaAR signaling required for diet-induced thermogenesis and obesity resistance.
6 *Science* **297**:843-845. doi: 10.1126/science.1073160
- 7 Badman MK, Pissios P, Kennedy AR, Koukos G, Flier JS, Maratos-Flier E. 2007. Hepatic
8 fibroblast growth factor 21 is regulated by PPAR α and is a key mediator of hepatic
9 lipid metabolism in ketotic states. *Cell Metabolism* **5**:426-437. doi:
10 10.1016/j.cmet.2007.05.002
- 11 Bagchi RA, Ferguson BS, Stratton MS, Hu T, Cavaasin MA, Sun L, Lin YH, Liu D, Londono
12 P, Song K, Pino MF, Sparks LM, Smith SR, Scherer PE, Collins S, Seto E, McKinsey
13 TA. 2018. HDAC11 suppresses the thermogenic program of adipose tissue via BRD2.
14 *The Journal of Clinical Investigation* **3**:e120159. doi: 10.1172/jci.insight.120159
- 15 Boström P, Wu J, Jedrychowski MP, Korde A, Ye L, Lo JC, Rasbach KA, Boström EA,
16 Choi JH, Long JZ, Kajimura S, Zingaretti MC, Vind BF, Tu H, Cinti S, Højlund K, Gygi
17 SP, Spiegelman BM. 2012. A PGC1- α -dependent myokine that drives brown-fat-like
18 development of white fat and thermogenesis. *Nature* **481**:463–468. doi:
19 10.1038/nature10777
- 20 Dutchak PA, Katafuchi T, Bookout AL, Choi JH, Yu RT, Mangelsdorf DJ, Kliewer SA. 2012.
21 Fibroblast growth factor-21 regulates PPAR γ activity and the antidiabetic actions of
22 thiazolidinediones. *Cell* **148**:556-567. doi: 10.1016/j.cell.2011.11.062
- 23 Fisher FM, Kleiner S, Douris N, Fox EC, Mepani RJ, Verdeguer F, Wu J, Kharitonov A,
24 Flier JS, Maratos-Flier E, Spiegelman BM. 2012. FGF21 regulates PGC-1 α and
25 browning of white adipose tissues in adaptive thermogenesis. *Genes & Development*
26 **26**:271-281. doi: 10.1101/gad.177857.111
- 27 Hansen JB, Jørgensen C, Petersen RK, Hallenborg P, De Matteis R, Bøye HA, Petrovic N,
28 Enerbäck S, Nedergaard J, Cinti S, te Riele H, Kristiansen K. 2004. Retinoblastoma
29 protein functions as a molecular switch determining white versus brown adipocyte

1 differentiation. *Proceedings of the National Academy of Sciences of USA*
2 **101**:4112-4117. doi: 10.1073/pnas.0301964101. Epub 2004 Mar 15

3 Hao RH, Guo Y, Dong SS, Weng GZ, Yan H, Zhu DL, Chen XF, Chen JB, Yang TL. 2016.
4 Associations of plasma FGF2 levels and polymorphisms in the FGF2 gene with obesity
5 phenotypes in Han Chinese population. *Scientific Reports* **6**:19868. doi:
6 10.1038/srep19868

7 Hurley MM, Lee SK, Raisz LG, Bernecker P, Lorenzo J. 1998. Basic fibroblast growth
8 factor induces osteoclast formation in murine bone marrow cultures. *Bone* **22**:309-316.
9 doi: 10.1016/s8756-3282(97)00292-5

10 Jonker JW, Suh JM, Atkins AR, Ahmadian M, Li P, Whyte J, He M, Juguilon H, Yin YQ,
11 Phillips CT, Yu RT, Olefsky JM, Henry RR, Downes M, Evans RM. 2012. A
12 PPAR γ -FGF1 axis is required for adaptive adipose remodelling and metabolic
13 homeostasis. *Nature* **485**:391-394. doi: 10.1038/nature10998

14 Kakudo N, Shimotsuma A, Kusumoto K. 2007. Fibroblast growth factor-2 stimulates
15 adipogenic differentiation of human adipose-derived stem cells. *Biochemical and*
16 *Biophysical Research Communications* **359**:239-244. doi: 10.1016/j.bbrc.2007.05.070.
17 Epub 2007 May 21

18 Kawaguchi N, Toriyama K, Nicodemou-Lena E, Inou K, Torii S, Kitagawa Y. 1998. De
19 novo adipogenesis in mice at the site of injection of basement membrane and basic
20 fibroblast growth factor. *Proceedings of the National Academy of Sciences of USA*
21 **95**:1062–1066. doi: 10.1073/pnas.95.3.1062

22 Kim S, Ahn C, Bong N, Choe S, Lee DK. 2015. Biphasic effects of FGF2 on adipogenesis.
23 *PLOS ONE* **10**:e0120073. doi: 10.1371/journal.pone.0120073. eCollection 2015

24 Montero A, Okada Y, Tomita M, Ito M, Tsurukami H, Nakamura T, Doetschman T, Coffin
25 JD, Hurley MM. 2000. Disruption of the fibroblast growth factor-2 gene results in
26 decreased bone mass and bone formation. *The Journal of Clinical Investigation*
27 **105**:1085-1093. doi: 10.1172/JCI8641

- 1 Poekes L, Lanthier N, Leclercq IA. 2015. Brown adipose tissue: a potential target in the
2 fight against obesity and the metabolic syndrome. *Clinical Science* **129**:933-949. doi:
3 10.1042/CS20150339
- 4 Powers CJ, McLeskey SW, Wellstein A. 2000. Fibroblast growth factors, their receptors
5 and signaling. *Endocrine-Related Cancer* **7**:165-197. doi: 10.1677/erc.0.0070165
- 6 Puigserver P, Spiegelman BM. 2003. Peroxisome proliferator-activated receptor-gamma
7 coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator.
8 *Endocrine Reviews* **24**:78-90. doi: 10.1210/er.2002-0012
- 9 Raballo R, Rhee J, Lyn-Cook R, Leckman JF, Schwartz ML, Vaccarino FM. 2000. Basic
10 fibroblast growth factor (Fgf2) is necessary for cell proliferation and neurogenesis in the
11 developing cerebral cortex. *The Journal of Neuroscience* **20**:5012-5023. doi:
12 10.1523/JNEUROSCI.20-13-05012.2000
- 13 Rogers NH. 2015. Brown adipose tissue during puberty and with aging. *Annals of*
14 *Medicine* **47**:142-149. doi: 10.3109/07853890.2014.914807. Epub 2014 Jun 3
- 15 Romanatto T, Roman EA, Arruda AP, Denis RG, Solon C, Milanski M, Moraes JC,
16 Bonfleur ML, Degasperi GR, Picardi PK, Hirabara S, Boschero AC, Curi R, Velloso LA.
17 2016. Deletion of tumor necrosis factor-alpha receptor 1 (TNFR1) protects against
18 diet-induced obesity by means of increased thermogenesis. *Journal of Biological*
19 *Chemistry* **291**:26934. doi: 10.1074/jbc.A109.030874.
- 20 Rosen ED, Spiegelman BM. 2014. What we talk about when we talk about fat. *Cell*
21 **156**:20-44. doi: 10.1016/j.cell.2013.12.012
- 22 Saito M, Okamatsu-Ogura Y, Matsushita M, Watanabe K, Yoneshiro T, Nio-Kobayashi J,
23 Iwanaga T, Miyagawa M, Kameya T, Nakada K, Kawai Y, Tsujisaki M. 2009. High
24 incidence of metabolically active brown adipose tissue in healthy adult humans: effects
25 of cold exposure and adiposity. *Diabetes* **58**:1526-1531. doi: 10.2337/db09-0530. Epub
26 2009 Apr 28
- 27 Sakaue H, Konishi M, Ogawa W, Asaki T, Mori T, Yamasaki M, Takata M, Ueno H, Kato S,
28 Kasuga M, Itoh N. 2002. Requirement of fibroblast growth factor 10 in development of
29 white adipose tissue. *Genes & Development* **16**:908-912. doi: 10.1101/gad.983202

1 Seale P, Conroe HM, Estall J, Kajimura S, Frontini A, Ishibashi J, Cohen P, Cinti S,
2 Spiegelman BM. 2011. Prdm16 determines the thermogenic program of subcutaneous
3 white adipose tissue in mice. *The Journal of Clinical Investigation* **121**:96-105. doi:
4 10.1172/JCI44271. Epub 2010 Dec 1

5 Stanford KI, Middelbeek RJ, Townsend KL, An D, Nygaard EB, Hitchcox KM, Markan KR,
6 Nakano K, Hirshman MF, Tseng YH, Goodyear LJ. 2013. Brown adipose tissue
7 regulates glucose homeostasis and insulin sensitivity. *The Journal of Clinical*
8 *Investigation* **123**:215-223. doi: 10.1172/JCI62308. Epub 2012 Dec 10

9 Than A, He HL, Chua SH, Xu D, Sun L, Leow MK, Chen P. 2015. Apelin enhances brown
10 adipogenesis and browning of white adipocytes. *Journal of Biological Chemistry*
11 **290**:14679–14691. doi: 10.1074/jbc.M115.643817. Epub 2015 Apr 30

12 van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink
13 GJ, Bouvy ND, Schrauwen P, Teule GJ. 2009. Cold-activated brown adipose tissue in
14 healthy men. *The New England Journal of Medicine* **360**:1500-1508. doi:
15 10.1056/NEJMoa0808718

16 Villarroya F, Vidal-Puig A. 2013. Beyond the sympathetic tone: the new brown fat
17 activators. *Cell Metabolism* **17**:638-643. doi: 10.1016/j.cmet.2013.02.020

18 Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J,
19 Savisto NJ, Enerbäck S, Nuutila P. 2009. Functional brown adipose tissue in healthy
20 adults. *The New England Journal of Medicine* **360**:1518-1525. doi:
21 10.1056/NEJMoa0808949

22 Wang H, Zhang Y, Yehuda-Shnaidman E, Medvedev AV, Kumar N, Daniel KW, Robidoux
23 J, Czech MP, Mangelsdorf DJ, Collins S. 2008. Liver X receptor alpha is a
24 transcriptional repressor of the uncoupling protein 1 gene and the brown fat phenotype.
25 *Molecular and Cellular Biology* **28**:2187-2200. doi: 10.1128/MCB.01479-07. Epub 2008
26 Jan 14

27 Whittle AJ, Carobbio S, Martins L, Slawik M, Hondares E, Vázquez MJ, Morgan D,
28 Csikasz RI, Gallego R, Rodriguez-Cuenca S, Dale M, Virtue S, Villarroya F, Cannon B,
29 Rahmouni K, López M, Vidal-Puig A. 2012. BMP8B increases brown adipose tissue

1 thermogenesis through both central and peripheral actions. *Cell* **149**:871–885. doi:
2 10.1016/j.cell.2012.02.066

3 Wu J, Boström P, Sparks LM, Ye L, Choi JH, Giang AH, Khandekar M, Virtanen KA,
4 Nuutila P, Schaart G, Huang K, Tu H, van Marken Lichtenbelt WD, Hoeks J, Enerbäck
5 S, Schrauwen P, Spiegelman BM. 2012. Beige adipocytes are a distinct type of
6 thermogenic fat cell in mouse and human. *Cell* **150**:366-376. doi:
7 10.1016/j.cell.2012.05.016. Epub 2012 Jul 12

8 Wu Z, Puigserver P, Andersson U, Zhang C, Adelmant G, Mootha V, Troy A, Cinti S,
9 Lowell B, Scarpulla RC, Spiegelman BM. 1999. Mechanisms controlling mitochondrial
10 biogenesis and respiration through the thermogenic coactivator PGC-1. *Cell*
11 **98**:115-124. doi: 10.1016/S0092-8674(00)80611-X

12 Xiao L, Sobue T, Esliger A, Kronenberg MS, Coffin JD, Doetschman T, Hurley MM. 2010.
13 Disruption of the Fgf2 gene activates the adipogenic and suppresses the osteogenic
14 program in mesenchymal marrow stromal stem cells. *Bone* **47**:360-370. doi:
15 10.1016/j.bone.2010.05.021. Epub 2010 May 25

16 Xue B, Coulter A, Rim JS, Koza RA, Kozak LP. 2005. Transcriptional synergy and the
17 regulation of Ucp1 during brown adipocyte induction in white fat depots. *Molecular and*
18 *Cellular Biology* **25**: 8311-8322. doi: 10.1128/MCB.25.18.8311-8322.2005

19 Yao L, Cui X, Chen Q, Yang X, Fang F, Zhang J, Liu G, Jin W, Chang Y. 2017.
20 Cold-inducible SIRT6 regulates thermogenesis of brown and beige fat. *Cell Reports*
21 **20**:641-654. doi: 10.1016/j.celrep.2017.06.069

22 Zeve D, Tang W, Graff J. 2009. Fighting fat with fat: the expanding field of adipose stem
23 cells. *Cell Stem Cell* **5**:472-481. doi: 10.1016/j.stem.2009.10.014

24 Zhou M, Sutliff RL, Paul RJ, Lorenz JN, Hoying JB, Haudenschild CC, Yin M, Coffin JD,
25 Kong L, Kranias EG, Luo W, Boivin GP, Duffy JJ, Pawlowski SA, Doetschman T. 1998.
26 Fibroblast growth factor 2 control of vascular tone. *Nature Medicine* **4**:201-207. doi:
27 10.1038/nm0298-201